Ogata et al., since the early 2000s, identified in several papers CD117, expressed by myeloid progenitors, and CD56 and CD7, usually expressed in other-than myeloid lineages, as markers of higher blast count, evolution to AML and poor prognosis. Here, NCAM1 is linked to acute myeloid leukemia.